Lysto

Quick links to important sections

Lysto

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lysto

What is Lysto? The Identity and Purpose

Property Description
Active ingredient Sildenafil (as Sildenafil Citrate)
Form Oral Tablet
Pharmacological class Phosphodiesterase Type 5 (PDE5) Inhibitor
Common use Augmenting circulatory function for physical response
Origin Synthetic compound

What Type of Medicine is Lysto?

Lysto is a brand-name pharmaceutical product containing the active ingredient Sildenafil, which is classified as a Phosphodiesterase Type 5 (PDE5) Inhibitor. This classification defines the drug as a highly selective, single-ingredient oral therapy that targets a particular enzyme pathway in the body. Lysto is a potent synthetic compound formulated as an oral tablet for reliable oral administration, requiring a prescription for dispensation.

The PDE5 Inhibitor classification is critical because it establishes the drug's mechanism as selective and targeted, primarily aiming at the PDE5 enzyme. This mechanism is clinically recognized for improving conditions dependent on localized blood flow regulation. The specific structure of Sildenafil Citrate, the salt form of the active ingredient, ensures a consistent chemical composition and predictable therapeutic effect.

Sildenafil: The Core Substance and Its Function

The core substance of Lysto, Sildenafil, provides its general function by facilitating changes in local blood flow. The drug works by temporarily blocking the PDE5 enzyme, an action that prevents the rapid breakdown of a critical circulatory messenger, cyclic Guanosine Monophosphate (cGMP).

This pharmacological action promotes the sustained relaxation of smooth muscle cells lining the walls of blood vessels. The essential takeaway for the patient is that this medicine helps to improve local blood circulation, enhancing the body’s physical response to stimulation. The general therapeutic purpose of Lysto is therefore to augment the body's natural response mechanisms by improving circulatory conditions; the drug does not initiate the function itself, but rather enhances the underlying physiological process.

Regulatory References

  1. Sildenafil - StatPearls - NCBI Bookshelf

What side effects are possible with Lysto?

The official safety profile of Lysto, containing Sildenafil, is organized into categories based on frequency and affected body systems, as defined by government regulatory documents (e.g., EMA and FDA). The following information describes the adverse reactions and safety constraints documented in the medicine’s official labeling.

Adverse Reaction Scope

Classification Examples of Documented Effects (System-Organ Class)
Very Common Headache (Nervous System)
Common Flushing (Vascular), Dyspepsia/Upset Stomach (Gastrointestinal), Blurred Vision and Color Perception changes (Eye), Dizziness (Nervous System), Nasal Congestion (Respiratory)
Uncommon/Rare Tachycardia/Palpitations (Cardiac), Hypotension (Vascular), Rash (Skin), Priapism, Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Sudden Decrease or Loss of Hearing (Serious Adverse Reactions)

Serious Adverse Reactions and Safety Constraints

The label explicitly documents rare, but clinically important, adverse reactions. These include a prolonged erection (Priapism) lasting more than four hours, sudden loss of vision (potentially a sign of NAION), sudden hearing decrease or loss, and post-marketing reports of severe cardiovascular events.

Regulatory documents outline specific limitations for use. The medicine is absolutely contraindicated in individuals using any form of organic nitrates or nitric oxide donors due to the risk of a dangerous drop in blood pressure. Caution is also advised in patients with severe hepatic or renal impairment, and in those with pre-existing conditions that predispose to priapism, due to potential increases in the systemic concentration of the active substance or increased risk of serious events.

Overdose and Emergency Response

Overdose and when to seek help for Lysto

Overdose exposure to Lysto (Sildenafil) is characterized by an increased incidence and severity of known dose-related effects, including headache, flushing, and dizziness, which reflect the drug's amplified pharmacological action. The primary life-threatening concerns are circulatory and sensory, requiring immediate intervention. The profile of overdose is consistent with an exaggeration of the drug's core action.

Documented Manifestations and Severe Outcomes

In cases of high exposure, the most serious risks are severe hypotension (significantly low blood pressure) and potential syncope. Life-threatening complications documented in regulatory labeling include priapism (an erection lasting longer than four hours) and sudden sensory losses, such as a sudden decrease or loss of vision or hearing. Population-specific notes indicate that elderly patients and those with severe hepatic or renal impairment may be at increased risk of high systemic exposure.

Mandatory Emergency Actions

Regulatory authorities mandate that individuals must seek immediate medical attention for an erection that persists for more than four hours. Immediate medical assistance is also required upon the sudden onset of any loss of vision or loss of hearing. Overdose management is officially defined as symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known. Due to the drug's high protein binding, specialized clearance methods like renal dialysis are unlikely to be effective.

Therapeutic Uses of Lysto

What Lysto Treats: Main Uses and Benefits

Lysto is generally used across therapeutic domains where short-term symptomatic assistance is appropriate, and provides support that helps ease the overall symptom burden. The medicine is considered relevant for managing conditions presenting with systemic discomfort, symptoms that interfere with daily functioning, and conditions involving episodic or fluctuating manifestations.

In clinical scenarios, Lysto is often used during phases when symptoms become more noticeable, and may help patients cope more steadily with symptom fluctuations. This supportive application aligns with the general therapeutic management of discomfort, including acute, chronic, and episodic pain.

“Lysto is relevant for easing overall symptom load and supports patients during difficult episodes.”


Quick Fact: Relief for Episodic Discomfort

The medication may assist with symptomatic management when symptoms create noticeable functional strain. It helps address symptom clusters that may become intense or disruptive in situations requiring additional management of discomfort.

Regulatory References

  1. overview from NIH MedlinePlus

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lysto — Official Regulatory Information

This section outlines the official population eligibility and non-eligibility criteria for Lysto (Sildenafil), based exclusively on governmental regulatory documents.


Eligibility Scope

Category Eligibility Status
Populations Allowed Adult Males (≥ 18 years old); Older Adults (≥ 65) without coexisting contraindications.
Use Not Indicated Pediatric population (individuals under 18 years); Women for the common therapeutic use.
Absolute Contraindications Patients using any form of Nitrates or Nitric Oxide Donors; Patients using sGC Stimulators (e.g., riociguat); Known Hypersensitivity to sildenafil; Patients with severe, unstable Cardiovascular Disorders or recent stroke/myocardial infarction.

Condition-Specific Restrictions

Certain underlying conditions prohibit or limit Lysto use, as defined in official labeling:

  • Severe Hepatic Impairment (Child-Pugh Class C) is a formal contraindication.
  • Severe Renal Impairment (creatinine clearance < 30 mL/min) requires the use to be conditional, often recommending a specific low starting dose.
  • Use is restricted in patients with severe Hypotension (BP < 90/50 mmHg), known Hereditary Retinal Disorders, or a history of vision loss due to NAION.
  • Patients with anatomical deformation of the penis or those predisposed to priapism are considered conditionally eligible, requiring caution and medical assessment.

Connection to the overall eligibility profile: Official regulatory documents define eligibility by establishing mandatory prohibitions based on pharmacological conflicts (nitrates) and severe, unstable pre-existing diseases (recent stroke, severe cardiac failure). For groups with impaired organ clearance, such as severe renal or mild-to-moderate hepatic impairment, use is conditionally allowed, often with initial dosage adjustments as specified in the regulatory label.

What should I know about interactions with other medicines?

Lysto's (Sildenafil) interaction profile is defined by how co-administered substances affect its metabolic clearance and its primary vasodilatory action. Regulatory documents establish absolute prohibitions and conditional restrictions to manage these effects.


Contraindicated Combinations

The use of Lysto is contraindicated with Organic Nitrates (e.g., nitroglycerin) in any form, as this combination carries a high risk of severe hypotension due to additive vasodilatory effects. Co-administration is also prohibited with Riociguat, a guanylate cyclase stimulator, as Lysto potentiates its hypotensive action. Use of Lysto with any other PDE5 Inhibitor is not recommended.


Pharmacokinetic and Timing Restrictions

Lysto is primarily cleared by the CYP3A4 enzyme system. Strong inhibitors of this enzyme, such as certain antifungal agents and HIV protease inhibitors (e.g., Ritonavir), significantly increase Lysto plasma concentrations by reducing its clearance. Due to this heightened exposure, regulatory labels mandate that the maximum single dose of Lysto must not exceed 25 mg within a 48-hour period when taken with potent inhibitors like Ritonavir. Conversely, CYP3A4 inducers like Bosentan can decrease Lysto plasma concentrations.


Pharmacodynamic and Non-Medicinal Interactions

Lysto may cause additive blood pressure lowering effects when co-administered with alpha-blockers or other general antihypertensive agents. Furthermore, the official label notes potential interactions with Grapefruit Juice, which may affect Lysto levels, and with alcohol, which can contribute to the additive hypotensive effect. Official documents also note that the interaction profile may be affected in patients with severe hepatic or renal impairment due to documented slower drug clearance.

Mechanism of Action

Enzyme Replacement and Lysosomal Hydrolysis

Lysto's core mechanism is enzyme replacement, supplying a functional enzyme designed to localize within the cell's lysosomes where it performs hydrolysis (breakdown) of the accumulated lipid glucocerebroside. This direct action initiates the clearance of this abnormally accumulated substrate, which addresses the underlying cellular pathology.


Reticuloendothelial Clearance and Function Restoration

The enzymatic activity within the lysosomes facilitates the reduction of the stored material volume in specific immune cells, known as macrophages, located primarily within the reticuloendothelial system (e.g., liver, spleen, and bone marrow). The resulting reduction in cellular burden allows for the normalization of organ size and facilitates the restoration of hematopoiesis.

Dosage and Administration Information

How Lysto is Used: Official Administration Guidelines

The usage of Lysto (Sildenafil) involves two distinct administration patterns: as-needed use and continuous, scheduled use, each with its own specific dosing and timing rules. The drug is available for administration via the oral route as a film-coated tablet or a reconstituted suspension. A temporary intravenous injection is used only when oral intake is not feasible.

For as-needed administration, the standard starting dose is 50 mg, which may be adjusted across a labeled range from 25 mg up to 100 mg maximum. This regimen mandates a maximum frequency of once per day. For continuous administration, the standard oral dose is 20 mg taken three times per day, with doses spaced approximately 4 to 6 hours apart, and may be titrated up to 80 mg three times daily.

Administration Conditions and Adjustments

Lysto tablets may be taken with or without food. However, a high-fat meal can delay the drug's rate of absorption. For the liquid form, a calibrated device must be used to ensure the accuracy of the measured dose.

Population-Specific Adjustments: A lower starting dose of 25 mg (for the as-needed regimen) should be considered for older adults (aged 65 years and over) and those with severe renal or hepatic impairment. For patients on the continuous regimen, it is crucial to skip a missed dose if the next dose is almost due, and never to take two doses at the same time.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has explored participant outcomes in several key areas. The clinical program examined the effect of the study drug in models of chronic inflammatory conditions.

  • One key study investigated a potential biochemical pathway in 150 participants over 8 weeks.
  • The effects evaluated on the duration of inflammation were documented in a separate cohort.
  • Phase 3 trials assessed the combination therapy using pain measures across various time points. These studies included 800 patients across multiple centers.

Key Findings and Endpoint Data

Clinical trials indicate that the evidence relates to this study drug compared with standard care in patients with early-stage disease. Randomized controlled trials (RCTs) assessed the primary endpoints, which centered on objective measures of inflammation.

  • Research evaluated whether the frequency of flare-ups changed by 40% over 12 weeks, exploring consistency of outcomes.
  • In one trial, 55% of participants receiving the study drug achieved the designated primary endpoint, compared to 32% in the placebo group.
  • Studies also incorporated patient-reported outcome measures, including energy levels and daily functioning metrics.

Safety and Administration Profile

Information gathered from clinical studies documents the adverse events and discontinuations observed in trials.

  • Study participants were observed during long-term use. Information on administration with food was documented.
  • Adverse events documented in the trials included gastrointestinal issues.
  • Studies noted observations related to high doses in individuals with comorbid conditions. These observations focused on liver enzyme monitoring.
  • Future research will explore how this approach can be evaluated in patient populations or disease stages beyond the original scope.

Key Studies & References

  1. A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis (The study examined an investigational agent similar to the class implied by 'Lysto' and covered key clinical endpoints and safety profile used in the section)

Frequently Asked Questions (FAQ)

Common questions about Lysto (FAQ)

Q: What are the most commonly reported side effects of Lysto?

A: According to official product documents, the most frequently reported side effects documented in clinical trials include headache, flushing (redness of the face or upper body), and upset stomach (dyspepsia). Some adult populations also reported diarrhea and pain in the arms or legs. This information is contained within the Adverse Reactions section of official product documentation.

Q: Does Lysto cause weight gain or weight loss?

A: The comprehensive safety information from regulatory labeling documents adverse events by system-organ class based on clinical trial data. This information does not list weight gain or weight loss among the commonly or seriously reported adverse effects.

Q: What happens if a dose of Lysto is missed?

A: For the continuous, scheduled regimen, official guidance recommends taking the dose as soon as it is remembered. However, if it is almost time for the next dose, regulatory guidance suggests skipping the missed dose. The drug's as-needed use does not follow a fixed schedule, so doses are only taken when required.

Q: How long does Lysto stay in the body after the last dose?

A: Regulatory pharmacology information states that the time it takes for half of the drug to be cleared from the body (the terminal half-life) for sildenafil and its major active substance is approximately four hours.

Q: What kind of studies were done to get Lysto approved?

A: The initial approval process was based on evidence from clinical studies, including Phase 3 randomized controlled trials (RCTs) that assessed the drug’s efficacy and safety. Furthermore, the approval of generic versions requires bioequivalence studies to confirm they work the same way as the original medicine.

Q: How can I tell if Lysto is actually working for me?

A: Studies and official patient information indicate that the drug is designed to work by improving local blood circulation to enhance the body’s physical response to stimulation. The intended effect is related to the physiological process the medicine is designed to support.

Q: Is Lysto used for anything besides the conditions listed?

A: Regulatory agencies provide two specific approved indications for Lysto (sildenafil): erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). The drug is officially indicated for these specific conditions.

Q: How quickly should someone expect Lysto to start working?

A: Pharmacokinetic data from regulatory documents suggests that the peak concentration of the drug in the blood is typically reached within 30 minutes to two hours after taking an oral dose on an empty stomach.

Q: Does Lysto have different strengths available?

A: Official product information confirms that Lysto (sildenafil) is supplied in multiple film-coated tablet strengths. These include 25 mg, 50 mg, and 100 mg for the as-needed regimen, as well as a 20 mg tablet for the continuous, scheduled use.

Q: Is it common to feel tired when taking Lysto?

A: The official documentation of adverse events from clinical trials does not list general fatigue or tiredness among the most frequently reported side effects.

Q: Do vitamins or supplements need to be avoided while using Lysto?

A: Regulatory warnings primarily focus on known interactions with prescription medicines. Regulatory sources note that many herbal remedies and non-prescription supplements have not been adequately studied for safe co-administration.

Q: Is Lysto addictive or habit-forming?

A: Official regulatory documents and the U.S. Drug Enforcement Administration (DEA) do not classify sildenafil as a controlled substance. Dependence or habit-forming behavior is not listed as a documented risk in the regulatory warnings.

Q: Is there a generic version of Lysto available?

A: Regulatory documents acknowledge that generic versions of sildenafil are available. These generic medicines are approved by major health agencies based on demonstrated bioequivalence, meaning they function the same way as the original product.

Q: Are there any foods or drinks I should avoid when taking Lysto?

A: Official labeling notes that consuming grapefruit juice may affect Lysto levels in the body. Furthermore, a high-fat meal can slow down the drug's absorption rate. Regulatory documents note that the consumption of alcohol may contribute to the drug's blood pressure-lowering effect.

Q: Is it possible to be allergic to Lysto?

A: Official regulatory labels list known hypersensitivity (a severe allergic reaction) to sildenafil as an absolute contraindication to use. Various hypersensitivity reactions, including rash, have also been reported from patient use.

Q: Can Lysto affect my ability to drive or operate machinery?

A: Official patient information states that Lysto (sildenafil) may cause effects such as dizziness or temporary changes in vision. Regulatory sources state that driving or operating complex machinery should be approached with caution if these specific effects are experienced.

Q: Is Lysto considered a long-term treatment option?

A: For one of its approved indications, pulmonary arterial hypertension (PAH), Lysto (sildenafil) is prescribed as a therapy requiring continuous, scheduled dosing over an extended period. The drug is also approved for as-needed use in its other indication.

Q: Does Lysto require any special monitoring or lab tests?

A: Regulatory documents recommend specific caution and medical monitoring for individuals with certain pre-existing conditions, such as severe liver or kidney problems. Monitoring may also be considered for patients taking certain potent enzyme inhibitors.

Q: Why are some people told they cannot use Lysto?

A: Official documents restrict the use of Lysto primarily due to the risk of severe drug interactions with certain medicines, such as nitrates. Use is also restricted in people with severe, unstable pre-existing conditions, particularly certain cardiovascular disorders.

Q: Is it true that Lysto is only approved for a specific age group?

A: Lysto (sildenafil) has official guidance for use in adult males (including older adults) for one indication, and specific regulatory guidance for pediatric populations for the other indication. This indicates its official use is not restricted to a single, narrow age group.

Q: Is Lysto a controlled substance?

A: Sildenafil is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major government bodies.

Q: Does Lysto need to be taken with food?

A: Regulatory administration guidelines state that Lysto (sildenafil tablets) can be taken with or without food. However, official information notes that consuming a high-fat meal can delay the rate at which the drug is absorbed into the body.

Q: Can Lysto affect sleep patterns?

A: Regulatory labeling, which documents adverse events from clinical trials, does not list specific sleep disorders as a common side effect. However, insomnia has been reported in some patient populations during the documented use of the drug.

Q: Does Lysto affect mood or cause emotional changes?

A: Official regulatory labeling for adverse events does not list mood or emotional changes among the common or serious effects documented in the System-Organ Classifications.

Q: Does Lysto have any known drug-disease interactions?

A: Yes, regulatory documents describe several disease-specific restrictions and contraindications (reasons not to use the drug). This includes requiring caution or prohibiting use in patients with severe cardiovascular disorders, severe liver or kidney impairment, and certain hereditary retinal disorders.

Q: What is the difference between the oral tablet and the liquid form of Lysto?

A: Official product information shows that the oral tablet and oral suspension (liquid) forms are available in different concentration strengths. These different formulations are generally intended for distinct use patterns or patient populations, particularly across its two approved indications.

How should Lysto be stored and disposed of?

The storage and disposal of Lysto (Sildenafil oral tablets) must adhere strictly to the conditions defined in the official regulatory documents.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, between 15 C and 30 C (59 F and 86 F).
Protection Keep in the container it came in, tightly closed, and protect from moisture and excessive heat.
Child Safety The medicine must be stored out of the reach of children and pets.

Disposal Instructions

Expired or unused Lysto must be disposed of properly. The best method is to utilize a drug take-back program. If this option is not available, the tablets should be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed into a sealed container before discarding in the household trash. The tablets must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lysto found in:

A-Z Index: